Skip to main content

Table 3 Results of the primary analysis for a simulated cohort of 1000 patients diagnosed with TB

From: The potential of a multiplex high-throughput molecular assay for early detection of first and second line tuberculosis drug resistance mutations to improve infection control and reduce costs: a decision analytical modeling study

  No. of TB patients in cohort No. with (pre-)XDR No. (%) of (pre-) XDR diagnosed earlier c.t. base case Total No. of IPM among cohort; % Change c.t. base case No. of PNTPM; % Change c.t. base case % of all IPM Total cohort costsa (US$ 2013); % change c.t. base case Diagnostic costs (US$ 2013); % of total costs Deaths (n; % Change c.t. base case Need for re-treatment (n)b
Base case 1000 59    1,710   66   4 % $3,557,923 0 % $44,617 1.2 % 39.1 125
High-throughput MRD-assay:
A. following culture 1000 59 45 76 % 1,603 −6 % 76 +15 % 5 % $2,960,243 −17 % $39,837 1.3 % 40.1 (+2.5 %) 127 (+1.6 %)
B. Improved analytical sensitivity 1000 59 45 76 % 1,617 −5 % 71 +8 % 4 % $2,821,923 −21 % $48,816 1.7 % 40.1 (+2.5 %) 129 (+3.9 %)
C. Improved clinical accuracy 1000 59 57 96 % 1,604 −6 % 50 −24 % 3 % $2,937,299 −17 % $39,233 1.3 % 40.1 (+2.5 %) 124 (−0.4 %)
  1. IPM infectious person-months, c.t. compared to, PNTPM potential nosocomial transmission person-months; i.e. IPM in (pre-)XDR patients that may cause nosocomial transmission, MRD molecular resistance detection
  2. aTotal costs combine diagnostic, treatment, hospitalization costs
  3. b% change is the same for deaths and need for retreatment